Bone Biologics (BBLG) Debt to Equity (2016 - 2017)
Bone Biologics (BBLG) has disclosed Debt to Equity for 2 consecutive years, with -$1.97 as the latest value for Q3 2017.
- On a quarterly basis, Debt to Equity rose 8.14% to -$1.97 in Q3 2017 year-over-year; TTM through Sep 2017 was -$1.97, a 8.14% increase, with the full-year FY2016 number at -$1.05, changed N/A from a year prior.
- Debt to Equity was -$1.97 for Q3 2017 at Bone Biologics, roughly flat from -$1.97 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$1.05 in Q4 2016 to a low of -$4.44 in Q1 2016.